genOway Improves its Growth With Major Japanese Biopharmaceutical Companies
News Jun 14, 2010
genOway announces strong growth of its business with major Japanese biopharmaceutical companies
The three Japanese biopharmaceutical companies, now customers of genOway, rank among the top ten of the nation’s biopharmaceutical industry. The amount of the active contracts just exceeded €400,000.
These agreements cover the development and delivery of genetically modified animal models and particularly humanized models dedicated to pharmaceutical compound testing. Other contractual details were not disclosed.
Alexandre Fraichard, CEO of genOway, declared: “Japanese biopharmaceutical industry is beginning to show signs of recovery. We were able to drop back on the market since the second half of 2009 and are very pleased that three of the largest Japanese biopharmaceutical companies now make use of our services and added value solutions. It is very important for us to attend sustainably this market, the second in size after the United States. In fact, we are very confident in signing several contracts in Japan in the coming trimesters.”
Gene Therapy Could End Transfusions for Blood Disorder PatientsNews
Beta-thalassemia patients need a regular dose of red blood cells transfused into their body. A new gene therapy that edits faulty genes in the patients' cells could end this monthly ritual.READ MORE
How Do Plants Avoid UV Damage?News
Public health warnings against too much exposure to UV are based on sound advice: UV rays can damage DNA and cause cancers and other diseases. Plants, however, cannot avoid UV. A new study now shows how plants' DNA repair system helps combat constant UV exposure.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018
International Conference on Epigenetics and Epitranscriptomics
Sep 17 - Sep 18, 2018